{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:11:01Z","timestamp":1782439861705,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013986","name":"Government of the United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["U01FD005946"],"award-info":[{"award-number":["U01FD005946"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["U01FD005978"],"award-info":[{"award-number":["U01FD005978"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clgc.2024.102113","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:45:47Z","timestamp":1715096747000},"page":"102113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient Preferences for Benefit and Risk Associated With High Intensity Focused Ultrasound for the Ablation of Prostate Tissue in Men With Localized Prostate Cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"Olufemi","family":"Babalola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gebben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Tarver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hsuan","family":"(Joyce) Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Minhaj","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-1956","authenticated-orcid":false,"given":"Geoffrey A.","family":"Sonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3114-6083","authenticated-orcid":false,"given":"Charles J.","family":"Viviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2024.102113_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"10.1016\/j.clgc.2024.102113_bib0002","first-page":"S3","article-title":"Risk factors for prostate cancer","volume":"4","author":"Gann","year":"2002","journal-title":"Rev Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102113_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/PPO.0b013e318156ff65","article-title":"Active surveillance with selective radical treatment for localized prostate cancer","volume":"13","author":"van As","year":"2007","journal-title":"Cancer J"},{"issue":"11","key":"10.1016\/j.clgc.2024.102113_bib0004","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.2017.1652","article-title":"Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer","volume":"317","author":"Chen","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clgc.2024.102113_bib0005","first-page":"1","article-title":"United States experience with primary HIFU therapy for patients with low-risk prostate cancer: results of the Enlight trial","volume":"3","author":"Robertson","year":"2015","journal-title":"J Ther Ultrasound"},{"issue":"1","key":"10.1016\/j.clgc.2024.102113_bib0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.juro.2016.06.092","article-title":"Pathological, oncologic and functional outcomes of a prospective registry of salvage high intensity focused ultrasound ablation for radiorecurrent prostate cancer","volume":"197","author":"Siddiqui","year":"2017","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102113_bib0007","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1442-2042.2009.02389.x","article-title":"Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience","volume":"16","author":"Uchida","year":"2009","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102113_bib0008","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1464-410X.2010.09518.x","article-title":"High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy","volume":"107","author":"Uchida","year":"2011","journal-title":"BJU Int"},{"issue":"24","key":"10.1016\/j.clgc.2024.102113_bib0009","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1001\/jama.2016.5002","article-title":"High-intensity focused ultrasound for prostate cancer: novelty or innovation?","volume":"315","author":"Hu","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.clgc.2024.102113_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.juro.2018.04.066","article-title":"Prostate ablation using high intensity focused ultrasound: a literature review of the potential role for patient preference information","volume":"200","author":"Babalola","year":"2018","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102113_bib0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clgc.2024.102113_bib0012","unstructured":"Center for Devices and Radiological Health. United States Food and Drug Administration: Patient Preference Information\u2014Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; 2016. Available at https:\/\/www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM446680.pdf. Accessed November 8, 2021."},{"issue":"3","key":"10.1016\/j.clgc.2024.102113_bib0013","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2013.370","article-title":"Patients\u2019 and urologists\u2019 preferences for prostate cancer treatment: a discrete choice experiment","volume":"109","author":"de Bekker-Grob","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102113_bib0014","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/1557988318776123","article-title":"Patient preferences and urologist judgments on prostate cancer therapy in Japan","volume":"12","author":"Nakayama","year":"2018","journal-title":"Am J Men Health"},{"issue":"4","key":"10.1016\/j.clgc.2024.102113_bib0015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","article-title":"Patients\u2019 preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment","volume":"39","author":"Eliasson","year":"2017","journal-title":"Clin Ther"},{"issue":"7436","key":"10.1016\/j.clgc.2024.102113_bib0016","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/bmj.37972.497234.44","article-title":"Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment","volume":"328","author":"Sculpher","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.clgc.2024.102113_bib0017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JU.0000000000000754","article-title":"Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study","volume":"204","author":"Watson","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102113_bib0018","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clgc.2024.102113_bib0019","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2147\/PPA.S238833","article-title":"Preferences of patients with chronic hepatitis B\u2013A discrete choice experiment on the acceptability of functional cure","volume":"14","author":"Hardtstock","year":"2020","journal-title":"Patient Pref Adher"},{"issue":"7436","key":"10.1016\/j.clgc.2024.102113_bib0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","article-title":"Discrete choice experiments in health care","volume":"328","author":"Ryan","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.clgc.2024.102113_bib0021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102113_bib0022","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102113_bib0023","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","article-title":"Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study","volume":"68","author":"Ahmed","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102113_bib0024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1590\/S1677-55382011000200008","article-title":"Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly: a feasibility study with 10 years follow-up","volume":"37","author":"Fegoun","year":"2011","journal-title":"Int Braz J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102113_bib0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.clgc.2024.102113_bib0026","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.pcan.4500992","article-title":"Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer","volume":"11","author":"Lloyd","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.clgc.2024.102113_bib0027","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/bjc.2011.552","article-title":"Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer","volume":"106","author":"King","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2024.102113_bib0028","unstructured":"Clinical investigations for prostate tissue ablation devices\u2014guidance for industry and food and drug administration staff (fda.gov). Available at: Clinical Investigations for Prostate Tissue Ablation Devices\u2014Guidance for Industry and Food and Drug Administration Staff (fda.gov)"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T11:24:13Z","timestamp":1728041053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1558767324000843"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102113","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Preferences for Benefit and Risk Associated With High Intensity Focused Ultrasound for the Ablation of Prostate Tissue in Men With Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102113"}}